Dr Paul Mitchell – Overview of the SCLC Treatment Landscape: the Australian Experience
These videos are intended for healthcare professionals for informative purposes only. Click on the video above to watch Dr Paul Mitchell provide an overview of the SCLC treatment landscape in Australia.
SCLC Webinar Chapters
Introduction: Dr Paul Mitchell
Background: Small Cell Lung Cancer
IMpower 133: Atezolizumab + Carboplatin + etoposide in 1L ES-SCLC
CASPIAN Trial: Durvalumab +Tremilimumab + etoposide in ES-SCLC
ECOG-ACRIN EA5161 – Cisplatin/carboplatin + etoposide + nivolumab in ES-SCLC
Keynote- 606. Pembrolizumab + etoposide +Cisplatin/Carboplatin in stage IV SCLC
Summary ES-SCLC: Key first-line IO trials
Checkmate 451 – Maintenance strategy of Immunotherapy
Biomarkers (PD-L1 AND TMB)
ES-SCLC: Adding Thoracic Radiotherapy and TROG Phase 2 study
Limited Stage small cell lung cancer (LS-SCLC)
Second line options and beyond
Summary of 1st line therapies in SCLC
Zepzelca Access Program Analysis (SCLC)
ZEPZELCA® is a registered trademark of PharmaMar SA. ZEPZELCA® is under license from PharmaMar SA.